24. Refractory Angina

go back to reference Jolicoeur EM, Granger CB, Henry TD, et al. Clinical and research issues regarding chronic advanced coronary artery disease: part I: contemporary and emerging therapies. Am Heart J. 2008;155(3):418–34.PubMedCrossRef Jolicoeur EM, Granger CB, Henry TD, et al. Clinical and research issues regarding chronic advanced coronary artery disease: part I: contemporary and emerging therapies. Am Heart J. 2008;155(3):418–34.PubMedCrossRef

go back to reference Jolicoeur EM, Ohman EM, Temple R, et al. Clinical and research issues regarding chronic advanced coronary artery disease part II: trial design, outcomes, and regulatory issues. Am Heart J. 2008;155(3):435–44.PubMedCrossRef Jolicoeur EM, Ohman EM, Temple R, et al. Clinical and research issues regarding chronic advanced coronary artery disease part II: trial design, outcomes, and regulatory issues. Am Heart J. 2008;155(3):435–44.PubMedCrossRef

go back to reference Mannheimer C, Camici P, Chester MR, et al. The problem of chronic refractory angina; report from the ESC joint study group on the treatment of refractory angina. Eur Heart J. 2002;23(5):355–70.PubMedCrossRef Mannheimer C, Camici P, Chester MR, et al. The problem of chronic refractory angina; report from the ESC joint study group on the treatment of refractory angina. Eur Heart J. 2002;23(5):355–70.PubMedCrossRef

go back to reference Gibbons RJ, Abrams J, Chatterjee K, et al. American College of Cardiology. American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina – summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). J Am Coll Cardiol. 2003;41(1):159–68.PubMedCrossRef Gibbons RJ, Abrams J, Chatterjee K, et al. American College of Cardiology. American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina – summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). J Am Coll Cardiol. 2003;41(1):159–68.PubMedCrossRef

go back to reference Mukherjee D, Bhatt DL, Roe MT, Patel V, Ellis SG. Direct myocardial revascularization and angiogenesis – how many patients might be eligible? Am J Cardiol. 1999;84(5):598–600.PubMedCrossRef Mukherjee D, Bhatt DL, Roe MT, Patel V, Ellis SG. Direct myocardial revascularization and angiogenesis – how many patients might be eligible? Am J Cardiol. 1999;84(5):598–600.PubMedCrossRef

go back to reference Williams B, Menon M, Satran D, et al. Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality. Catheter Cardiovasc Interv. 2010;75(6):886–91.PubMed Williams B, Menon M, Satran D, et al. Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality. Catheter Cardiovasc Interv. 2010;75(6):886–91.PubMed

go back to reference Mukherjee D, Comella K, Bhatt DL, Roe MT, Patel V, Ellis SG. Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization. Am Heart J. 2001;142(1):72–4.PubMedCrossRef Mukherjee D, Comella K, Bhatt DL, Roe MT, Patel V, Ellis SG. Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization. Am Heart J. 2001;142(1):72–4.PubMedCrossRef

go back to reference Kandzari DE, Lam LC, Eisenstein EL, et al. Advanced coronary artery disease: appropriate end points for trials of novel therapies. Am Heart J. 2001;142(5):843–51.PubMedCrossRef Kandzari DE, Lam LC, Eisenstein EL, et al. Advanced coronary artery disease: appropriate end points for trials of novel therapies. Am Heart J. 2001;142(5):843–51.PubMedCrossRef

go back to reference Allen KB, Dowling RD, Fudge TL, et al. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. N Engl J Med. 1999;341(14):1029–36.PubMedCrossRef Allen KB, Dowling RD, Fudge TL, et al. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. N Engl J Med. 1999;341(14):1029–36.PubMedCrossRef

go back to reference Burkhoff D, Schmidt S, Schulman SP, et al. Transmyocardial laser revascularization compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomized trial. ATLANTIC investigators. Angina treatments – lasers and normal therapies in comparison. Lancet. 1999;354(9182):885–90.PubMedCrossRef Burkhoff D, Schmidt S, Schulman SP, et al. Transmyocardial laser revascularization compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomized trial. ATLANTIC investigators. Angina treatments – lasers and normal therapies in comparison. Lancet. 1999;354(9182):885–90.PubMedCrossRef

go back to reference Frazier OH, March RJ, Horvath KA. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. N Engl J Med. 1999;341(14):1021–8.PubMedCrossRef Frazier OH, March RJ, Horvath KA. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. N Engl J Med. 1999;341(14):1021–8.PubMedCrossRef

go back to reference Oesterle SN, Sanborn TA, Ali N, et al. Percutaneous transmyocardial laser revascularization for severe angina: the PACIFIC randomised trial. Potential class improvement from intramyocardial channels. Lancet. 2000;356(9243):1705–10.PubMedCrossRef Oesterle SN, Sanborn TA, Ali N, et al. Percutaneous transmyocardial laser revascularization for severe angina: the PACIFIC randomised trial. Potential class improvement from intramyocardial channels. Lancet. 2000;356(9243):1705–10.PubMedCrossRef

go back to reference Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 2003;107(10):1359–65.PubMedCrossRef Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 2003;107(10):1359–65.PubMedCrossRef

go back to reference Kastrup J, Jorgensen E, Ruck A, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study: the Euroinject One Trial. J Am Coll Cardiol. 2005;45(7):982–8.PubMedCrossRef Kastrup J, Jorgensen E, Ruck A, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study: the Euroinject One Trial. J Am Coll Cardiol. 2005;45(7):982–8.PubMedCrossRef

go back to reference Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation. 2002;105(7):788–93.PubMedCrossRef Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation. 2002;105(7):788–93.PubMedCrossRef

go back to reference Stewart DJ, Hilton JD, Arnold JM, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of (AdVEGF121) versus maximum medical treatment. Gene Ther. 2006;13(21):1503–11.PubMedCrossRef Stewart DJ, Hilton JD, Arnold JM, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of (AdVEGF121) versus maximum medical treatment. Gene Ther. 2006;13(21):1503–11.PubMedCrossRef

go back to reference Henry TD, Grines CL, Watkins MW, et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol. 2007;50(11):1038–46.PubMedCrossRef Henry TD, Grines CL, Watkins MW, et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol. 2007;50(11):1038–46.PubMedCrossRef

go back to reference Henry TD, Satran D, Campbell AR, et al. Long-term mortality in patients with refractory angina. J Am Coll Cardiol. 2008;51:A227. Henry TD, Satran D, Campbell AR, et al. Long-term mortality in patients with refractory angina. J Am Coll Cardiol. 2008;51:A227.

go back to reference Bache RJ, Dymek DJ. Local and regional regulation of coronary vascular tone. Prog Cardiovasc Dis. 1981;24(3):191–212.PubMedCrossRef Bache RJ, Dymek DJ. Local and regional regulation of coronary vascular tone. Prog Cardiovasc Dis. 1981;24(3):191–212.PubMedCrossRef

go back to reference Lanza GA, Crea F. Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. Circulation. 2010;121(21):2317–25.PubMedCrossRef Lanza GA, Crea F. Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. Circulation. 2010;121(21):2317–25.PubMedCrossRef

go back to reference Michaels AD, McCullough PA, Soran OZ, et al. Primer: practical approach to the selection of patients for and application of EECP. Nat Clin Pract Cardiovasc Med. 2006;3(11):623–32.PubMedCrossRef Michaels AD, McCullough PA, Soran OZ, et al. Primer: practical approach to the selection of patients for and application of EECP. Nat Clin Pract Cardiovasc Med. 2006;3(11):623–32.PubMedCrossRef

go back to reference Baim DS, Grossman W. Grossman’s cardiac catheterization, angiography, and intervention. 7th ed. Philadelphia: Lippincott, Williams & Wilkins; 2006. Baim DS, Grossman W. Grossman’s cardiac catheterization, angiography, and intervention. 7th ed. Philadelphia: Lippincott, Williams & Wilkins; 2006.

go back to reference Khan SN, Dutka DP. A systematic approach to refractory angina. Curr Opin Support Palliat Care. 2008;2(4):247–51.PubMedCrossRef Khan SN, Dutka DP. A systematic approach to refractory angina. Curr Opin Support Palliat Care. 2008;2(4):247–51.PubMedCrossRef

go back to reference Cesar LA, Gowdak LH, Mansur AP. The metabolic treatment of patients with coronary artery disease: effects on quality of life and effort angina. Curr Pharm Des. 2009;15(8):841–9.PubMedCrossRef Cesar LA, Gowdak LH, Mansur AP. The metabolic treatment of patients with coronary artery disease: effects on quality of life and effort angina. Curr Pharm Des. 2009;15(8):841–9.PubMedCrossRef

go back to reference Chazov EI, Lepakchin VK, Zharova EA, et al. Trimetazidine in angina combination therapy – the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther. 2005;12(1):35–42.PubMedCrossRef Chazov EI, Lepakchin VK, Zharova EA, et al. Trimetazidine in angina combination therapy – the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther. 2005;12(1):35–42.PubMedCrossRef

go back to reference Ashrafian H, Horowitz JD, Frenneaux MP. Perhexiline. Cardiovasc Drug Rev. 2007;25(1):76–97.PubMedCrossRef Ashrafian H, Horowitz JD, Frenneaux MP. Perhexiline. Cardiovasc Drug Rev. 2007;25(1):76–97.PubMedCrossRef

go back to reference Killalea SM, Krum H. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. Am J Cardiovasc Drugs. 2001;1(3):193–204.PubMedCrossRef Killalea SM, Krum H. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. Am J Cardiovasc Drugs. 2001;1(3):193–204.PubMedCrossRef

go back to reference Yang EH, Barsness GW. Evolving treatment strategies for chronic refractory angina. Expert Opin Pharmacother. 2006;7(3):259–66.PubMedCrossRef Yang EH, Barsness GW. Evolving treatment strategies for chronic refractory angina. Expert Opin Pharmacother. 2006;7(3):259–66.PubMedCrossRef

go back to reference Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest. 2005;115(8):2047–58.PubMedCrossRef Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest. 2005;115(8):2047–58.PubMedCrossRef

go back to reference IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomised trial. Lancet. 2002;359(9314):1269–75.CrossRef IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomised trial. Lancet. 2002;359(9314):1269–75.CrossRef

go back to reference Hale SL, Shryock JC, Belardinelli L, Sweeney M, Kloner RA. Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol. 2008;44(6):954–67.PubMedCrossRef Hale SL, Shryock JC, Belardinelli L, Sweeney M, Kloner RA. Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol. 2008;44(6):954–67.PubMedCrossRef

go back to reference Fraser H, Belardinelli L, Wang L, Light PE, McVeigh JJ, Clanachan AS. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol. 2006;41(6):1031–8.PubMedCrossRef Fraser H, Belardinelli L, Wang L, Light PE, McVeigh JJ, Clanachan AS. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol. 2006;41(6):1031–8.PubMedCrossRef

go back to reference Takeo S, Tanonaka K, Shimizu K, Hirai K, Miyake K, Minematsu R. Beneficial effects of lidocaine and disopyramide on oxygen-deficiency-induced contractile failure and metabolic disturbance in isolated rabbit hearts. J Pharmacol Exp Ther. 1989;248(1):306–14.PubMed Takeo S, Tanonaka K, Shimizu K, Hirai K, Miyake K, Minematsu R. Beneficial effects of lidocaine and disopyramide on oxygen-deficiency-induced contractile failure and metabolic disturbance in isolated rabbit hearts. J Pharmacol Exp Ther. 1989;248(1):306–14.PubMed

go back to reference Noble D, Noble PJ. Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart. 2006;92 Suppl 4:1–5. Noble D, Noble PJ. Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart. 2006;92 Suppl 4:1–5.

go back to reference Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375–82.PubMedCrossRef Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375–82.PubMedCrossRef

go back to reference Chaitman BR, Pepine CJ, Parker JO, et al. Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309–16.PubMedCrossRef Chaitman BR, Pepine CJ, Parker JO, et al. Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309–16.PubMedCrossRef

go back to reference Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Erica I Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (efficacy of ranolazine in chronic angina) trial. J Am Coll Cardiol. 2006;48(3):566–75.PubMedCrossRef Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Erica I Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (efficacy of ranolazine in chronic angina) trial. J Am Coll Cardiol. 2006;48(3):566–75.PubMedCrossRef

go back to reference Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297(16):1775–83.PubMedCrossRef Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297(16):1775–83.PubMedCrossRef

go back to reference Bennett NM, Arndt TL, Iyer V, et al. Ranolazine refractory angina registry trial: 1-year results [abstract]. J Am Coll Cardiol. 2011;57:E1050. Bennett NM, Arndt TL, Iyer V, et al. Ranolazine refractory angina registry trial: 1-year results [abstract]. J Am Coll Cardiol. 2011;57:E1050.

go back to reference Egashira K, Hirooka Y, Kuga T, Mohri M, Takeshita A. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation. 1996;94(2):130–4.PubMedCrossRef Egashira K, Hirooka Y, Kuga T, Mohri M, Takeshita A. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation. 1996;94(2):130–4.PubMedCrossRef

go back to reference Lerman A, Burnett Jr JC, Higano ST, McKinley LJ, Holmes Jr DR. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 1998;97(21):2123–8.PubMedCrossRef Lerman A, Burnett Jr JC, Higano ST, McKinley LJ, Holmes Jr DR. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 1998;97(21):2123–8.PubMedCrossRef

go back to reference Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol. 1997;80(3):331–3.PubMedCrossRef Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol. 1997;80(3):331–3.PubMedCrossRef

go back to reference Sinvhal RM, Gowda RM, Khan IA. Enhanced external counterpulsation for refractory angina pectoris. Heart. 2003;89(8):830–3.PubMedCrossRef Sinvhal RM, Gowda RM, Khan IA. Enhanced external counterpulsation for refractory angina pectoris. Heart. 2003;89(8):830–3.PubMedCrossRef

go back to reference Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol. 1999;33(7):1833–40.PubMedCrossRef Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol. 1999;33(7):1833–40.PubMedCrossRef

go back to reference Feldman AM, Silver MA, Francis GS, et al. Enhanced external counterpulsation improves exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 2006;48(6):1198–205.PubMedCrossRef Feldman AM, Silver MA, Francis GS, et al. Enhanced external counterpulsation improves exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 2006;48(6):1198–205.PubMedCrossRef

go back to reference Kersten JR, Pagel PS, Chilian WM, Warltier DC. Multifactorial basis for coronary collateralization: a complex adaptive response to ischemia. Cardiovasc Res. 1999;43(1):44–57.PubMedCrossRef Kersten JR, Pagel PS, Chilian WM, Warltier DC. Multifactorial basis for coronary collateralization: a complex adaptive response to ischemia. Cardiovasc Res. 1999;43(1):44–57.PubMedCrossRef

go back to reference Braith RW, Conti CR, Nichols WW, et al. Enhanced external counterpulsation improves peripheral artery flow-mediated dilation in patients with chronic angina: a randomized sham-controlled study. Circulation. 2010;122(16):1612–20.PubMedCrossRef Braith RW, Conti CR, Nichols WW, et al. Enhanced external counterpulsation improves peripheral artery flow-mediated dilation in patients with chronic angina: a randomized sham-controlled study. Circulation. 2010;122(16):1612–20.PubMedCrossRef

go back to reference Bonetti PO, Barsness GW, Keelan PC, et al. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol. 2003;41(10):1761–8.PubMedCrossRef Bonetti PO, Barsness GW, Keelan PC, et al. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol. 2003;41(10):1761–8.PubMedCrossRef

go back to reference Michaels AD, Raisinghani A, Soran O, et al. The effects of enhanced external counterpulsation on myocardial perfusion in patients with stable angina: a multicenter radionuclide study. Am Heart J. 2005;150(5):1066–73.PubMedCrossRef Michaels AD, Raisinghani A, Soran O, et al. The effects of enhanced external counterpulsation on myocardial perfusion in patients with stable angina: a multicenter radionuclide study. Am Heart J. 2005;150(5):1066–73.PubMedCrossRef

go back to reference Akhtar M, Wu GF, Du ZM, Zheng ZS, Michaels AD. Effect of external counterpulsation on plasma nitric oxide and endothelin-1 levels. Am J Cardiol. 2006;98(1):28–30.PubMedCrossRef Akhtar M, Wu GF, Du ZM, Zheng ZS, Michaels AD. Effect of external counterpulsation on plasma nitric oxide and endothelin-1 levels. Am J Cardiol. 2006;98(1):28–30.PubMedCrossRef

go back to reference Kiernan TJ, Boilson BA, Tesmer L, Harbuzariu A, Simari RD, Barsness GW. Effect of enhanced external counterpulsation on circulating CD34+ progenitor cell subsets. Int J Cardiol. 2010 Sep 13. Kiernan TJ, Boilson BA, Tesmer L, Harbuzariu A, Simari RD, Barsness GW. Effect of enhanced external counterpulsation on circulating CD34+ progenitor cell subsets. Int J Cardiol. 2010 Sep 13.

go back to reference Campbell AR, Satran D, Zenovich AG, et al. Enhanced external counterpulsation improves systolic blood pressure in patients with refractory angina. Am Heart J. 2008;156(6):1217–22.PubMedCrossRef Campbell AR, Satran D, Zenovich AG, et al. Enhanced external counterpulsation improves systolic blood pressure in patients with refractory angina. Am Heart J. 2008;156(6):1217–22.PubMedCrossRef

go back to reference Norrsell H, Eliasson T, Mannheimer C, et al. Effects of pacing-induced myocardial stress and spinal cord stimulation on whole body and cardiac norepinephrine spillover. Eur Heart J. 1997;18(12):1890–6.PubMedCrossRef Norrsell H, Eliasson T, Mannheimer C, et al. Effects of pacing-induced myocardial stress and spinal cord stimulation on whole body and cardiac norepinephrine spillover. Eur Heart J. 1997;18(12):1890–6.PubMedCrossRef

go back to reference Eliasson T, Mannheimer C, Waagstein F, et al. Myocardial turnover of endogenous opioids and calcitonin-gene-related peptide in the human heart and the effects of spinal cord simulation on pacing-induced angina pectoris. Cardiology. 1998;89(3):170–7.PubMedCrossRef Eliasson T, Mannheimer C, Waagstein F, et al. Myocardial turnover of endogenous opioids and calcitonin-gene-related peptide in the human heart and the effects of spinal cord simulation on pacing-induced angina pectoris. Cardiology. 1998;89(3):170–7.PubMedCrossRef

go back to reference Hautvast RW, DeJongste MJ, Horst GJ, Blanksma PK, Lie KI. Angina pectoris refractory for conventional therapy – is neurostimulation a possible alternative treatment? Clin Cardiol. 1996;19(7):531–5.PubMedCrossRef Hautvast RW, DeJongste MJ, Horst GJ, Blanksma PK, Lie KI. Angina pectoris refractory for conventional therapy – is neurostimulation a possible alternative treatment? Clin Cardiol. 1996;19(7):531–5.PubMedCrossRef

go back to reference Hautvast RW, Blanksma PK, DeJongste MJ, et al. Effect of spinal cord stimulation on myocardial blood flow assessed by positron emission tomography in patients with refractory angina pectoris. Am J Cardiol. 1996;77(7):462–7.PubMedCrossRef Hautvast RW, Blanksma PK, DeJongste MJ, et al. Effect of spinal cord stimulation on myocardial blood flow assessed by positron emission tomography in patients with refractory angina pectoris. Am J Cardiol. 1996;77(7):462–7.PubMedCrossRef

go back to reference Mannheimer C, Eliasson T, Augustinsson LE, et al. Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris: The ESBY study. Circulation. 1998;97(12):1157–63.PubMedCrossRef Mannheimer C, Eliasson T, Augustinsson LE, et al. Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris: The ESBY study. Circulation. 1998;97(12):1157–63.PubMedCrossRef

go back to reference Ekre O, Eliasson T, Norrsell H, Wahrborg P, Mannheimer C. Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris. Long-term effects of spinal cord stimulation and coronary artery bypass grafting on quality of life and survival in the ESBY study. Eur Heart J. 2002;23(24):1938–45.PubMedCrossRef Ekre O, Eliasson T, Norrsell H, Wahrborg P, Mannheimer C. Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris. Long-term effects of spinal cord stimulation and coronary artery bypass grafting on quality of life and survival in the ESBY study. Eur Heart J. 2002;23(24):1938–45.PubMedCrossRef

go back to reference Zipes DP, Svorkdal N, Breman D, et al. Spinal cord simulation therapy for patients with refractory angina who are not candidates for revascularization. Eur Heart J. 2002;23:355–70.CrossRef Zipes DP, Svorkdal N, Breman D, et al. Spinal cord simulation therapy for patients with refractory angina who are not candidates for revascularization. Eur Heart J. 2002;23:355–70.CrossRef

go back to reference Heusch G, Baumgart D, Camici P, et al. Alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation. 2000;101(6):689–94.PubMedCrossRef Heusch G, Baumgart D, Camici P, et al. Alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation. 2000;101(6):689–94.PubMedCrossRef

go back to reference Tune JD, Richmond KN, Gorman MW, Feigl EO. Control of coronary blood flow during exercise. Exp Biol Med (Maywood). 2002;227(4):238–50. Tune JD, Richmond KN, Gorman MW, Feigl EO. Control of coronary blood flow during exercise. Exp Biol Med (Maywood). 2002;227(4):238–50.

go back to reference Chaturvedi A, Dash HH. Locked-in syndrome during stellate ganglion block. Indian J Anaesth. 2010;54(4):324–6.PubMedCrossRef Chaturvedi A, Dash HH. Locked-in syndrome during stellate ganglion block. Indian J Anaesth. 2010;54(4):324–6.PubMedCrossRef

go back to reference Henry TD. Review of preclinical and clinical results with vascular endothelial growth factors for therapeutic angiogenesis. Curr Interv Cardiol Rep. 2000;2(3):228–41.PubMed Henry TD. Review of preclinical and clinical results with vascular endothelial growth factors for therapeutic angiogenesis. Curr Interv Cardiol Rep. 2000;2(3):228–41.PubMed

go back to reference Giordano FJ, Ping P, McKirnan MD, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med. 1996;2(5):534–9.PubMedCrossRef Giordano FJ, Ping P, McKirnan MD, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med. 1996;2(5):534–9.PubMedCrossRef

go back to reference Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001;7(4):430–6.PubMedCrossRef Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001;7(4):430–6.PubMedCrossRef

go back to reference Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation. 2002;105:1291–7.PubMedCrossRef Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation. 2002;105:1291–7.PubMedCrossRef

go back to reference Grines CL, Watkins MW, Mahmarian JJ, et al. Angiogene GENe Therapy (AGENT-2) Study Group. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol. 2003;42(8):1339–47.PubMedCrossRef Grines CL, Watkins MW, Mahmarian JJ, et al. Angiogene GENe Therapy (AGENT-2) Study Group. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol. 2003;42(8):1339–47.PubMedCrossRef

go back to reference Stewart DJ, Kutryk MJ, Fitchett D, et al. NORTHERN Trial I. Mol Ther. 2009;17(6):1109–15.PubMedCrossRef Stewart DJ, Kutryk MJ, Fitchett D, et al. NORTHERN Trial I. Mol Ther. 2009;17(6):1109–15.PubMedCrossRef

go back to reference Ruel M, Beanlands RS, Lortie M, et al. Concomitant treatment with oral L-arginine improves the efficacy of surgical angiogenesis in patients with severe diffuse coronary artery disease: the endothelial modulation in angiogenic therapy randomized controlled trial. J Thorac Cardiovasc Surg. 2008;135(4):762.PubMedCrossRef Ruel M, Beanlands RS, Lortie M, et al. Concomitant treatment with oral L-arginine improves the efficacy of surgical angiogenesis in patients with severe diffuse coronary artery disease: the endothelial modulation in angiogenic therapy randomized controlled trial. J Thorac Cardiovasc Surg. 2008;135(4):762.PubMedCrossRef

go back to reference Erbs S, Linke A, Schachinger V, et al. Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the doppler substudy of the reinfusion of enriched progenitor cells and infarct remodeling in acute myocardial infarction (REPAIR-AMI) trial. Circulation. 2007;116(4):366–74.PubMedCrossRef Erbs S, Linke A, Schachinger V, et al. Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the doppler substudy of the reinfusion of enriched progenitor cells and infarct remodeling in acute myocardial infarction (REPAIR-AMI) trial. Circulation. 2007;116(4):366–74.PubMedCrossRef

go back to reference Losordo DW, Schatz RA, White CJ, et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation. 2007;115(25):3165–72.PubMedCrossRef Losordo DW, Schatz RA, White CJ, et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation. 2007;115(25):3165–72.PubMedCrossRef

go back to reference Losordo DW, Henry TD, Davidson C, et al. for the ACT34-CMI Investigators. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109(4):428-36. Losordo DW, Henry TD, Davidson C, et al. for the ACT34-CMI Investigators. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109(4):428-36.

go back to reference Horvath KA, Cohn LH, Cooley DA, et al. Transmyocardial laser revascularization: results of a multicenter trial with transmyocardial laser revascularization used as sole therapy for end-stage coronary artery disease. J Thorac Cardiovasc Surg. 1997;113(4):645–53.PubMedCrossRef Horvath KA, Cohn LH, Cooley DA, et al. Transmyocardial laser revascularization: results of a multicenter trial with transmyocardial laser revascularization used as sole therapy for end-stage coronary artery disease. J Thorac Cardiovasc Surg. 1997;113(4):645–53.PubMedCrossRef

go back to reference Leon MB, Kornowski R, Downey WE, et al. A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol. 2005;46(10):1812–9.PubMedCrossRef Leon MB, Kornowski R, Downey WE, et al. A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol. 2005;46(10):1812–9.PubMedCrossRef

go back to reference Yang EH, Barsness GW, Gersh BJ, Lerman A. Current and future treatment strategies for refractory angina. Mayo Clin Proc. 2004;79(10):1284–92.PubMedCrossRef Yang EH, Barsness GW, Gersh BJ, Lerman A. Current and future treatment strategies for refractory angina. Mayo Clin Proc. 2004;79(10):1284–92.PubMedCrossRef

go back to reference Vale PR, Losordo DW, Milliken CE, et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation. 2001;103:2138–43.PubMedCrossRef Vale PR, Losordo DW, Milliken CE, et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation. 2001;103:2138–43.PubMedCrossRef